Effective omalizumab interval prolongation in the treatment of chronic urticaria
Open Access
- 1 November 2020
- journal article
- letter
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (10) , 3667-3668.e1
Abstract
No abstract availableKeywords
Funding Information
- Novartis
This publication has 12 references indexed in Scilit:
- High-dose omalizumab use in patients with chronic spontaneous urticariaThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real‐world study in BelgiumJournal of the European Academy of Dermatology and Venereology, 2019
- Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticariaJournal of Allergy and Clinical Immunology, 2018
- How to discontinue omalizumab in chronic spontaneous urticaria?Allergy, 2018
- Omalizumab in chronic spontaneous urticariaAnnals of Allergy, Asthma & Immunology, 2018
- Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidenceExpert Opinion on Biological Therapy, 2018
- The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticariaAllergy, 2018
- Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation?Annals of Allergy, Asthma & Immunology, 2015
- Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticariaAllergologia et Immunopathologia, 2015
- An algorithm for treating chronic urticaria with omalizumab: Dose interval should be individualizedJournal of Allergy and Clinical Immunology, 2014